Contribute Try STAT+ Today

Smoking cessation pill Chantix just got a reprieve from the Food and Drug Administration: The Pfizer drug no longer needs to carry a black box warning label noting that users are at risk for serious side effects like suicidal thoughts and hostility.

Pfizer has been battling the dreadful publicity around Chantix’s potential neuropsychiatric side effects ever since the drug was approved about a decade ago. Sales, which were expected to place Chantix in blockbuster status, have plateaued in the years since approval — thanks, in part, to a spate of lawsuits that claimed the drug caused violent or suicidal behavior.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • Stat plus. You have the nerve to give me part of an article for my globe subscription and send me to a pay wall!. This is worse than reporting on tweets, which is pathetic journalism. I’ll be cancelling my globe subscription Monday.

Comments are closed.